Keystone Labs Keeps OTC Drugs In Plans After Court Orders Manufacturing Halt
Executive Summary
Keystone Labs agrees to cease manufacturing OTC drugs after repeat GMP violations following a 2013 FDA warning letter, including failure to investigate sources of contamination. Firm says it informed FDA it would outsource OTC product manufacturing and continue making hair and skin care cosmetic formulas.
You may also be interested in...
FDA Consumer Health Product Recalls For May 4-25, 2016
Recalls reported by FDA for OTC drugs, nutritionals and personal care products.
In Brief
New studies from Chanel researchers and Gettysburg College support makeup’s anti-aging effect. More news in brief.
Cosmetics Industry Awaits FDA’s Allergen List While Working To Inform GMP Rulemaking
The Independent Beauty Association does not yet have insight into what ingredients will be listed in the US FDA’s proposed rulemaking for cosmetic allergen labeling – due by 29 June – but is optimistic the agency will consult industry when it comes to setting the compliance timeline. Meanwhile, industry stakeholders are pushing for international harmonization in the agency’s cosmetic GMPs rulemaking.